- Home
- OTLK vs FOXX Comparison
OTLK vs FOXX Comparison
Compare OTLK & FOXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- FOXX
- Stock Information
- Founded
- OTLK 2010
- FOXX 2017
- Country
- OTLK United States
- FOXX United States
- Employees
- OTLK N/A
- FOXX N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- FOXX
- Sector
- OTLK Health Care
- FOXX
- Exchange
- OTLK Nasdaq
- FOXX Nasdaq
- Market Cap
- OTLK 48.3M
- FOXX 39.6M
- IPO Year
- OTLK 2016
- FOXX N/A
- Fundamental
- Price
- OTLK $1.71
- FOXX $5.50
- Analyst Decision
- OTLK Strong Buy
- FOXX
- Analyst Count
- OTLK 5
- FOXX 0
- Target Price
- OTLK $9.60
- FOXX N/A
- AVG Volume (30 Days)
- OTLK 823.9K
- FOXX 7.6K
- Earning Date
- OTLK 08-13-2025
- FOXX 08-15-2025
- Dividend Yield
- OTLK N/A
- FOXX N/A
- EPS Growth
- OTLK N/A
- FOXX N/A
- EPS
- OTLK 0.83
- FOXX N/A
- Revenue
- OTLK N/A
- FOXX $53,866,257.00
- Revenue This Year
- OTLK N/A
- FOXX N/A
- Revenue Next Year
- OTLK $379.84
- FOXX N/A
- P/E Ratio
- OTLK $2.06
- FOXX N/A
- Revenue Growth
- OTLK N/A
- FOXX 3899.98
- 52 Week Low
- OTLK $0.87
- FOXX $2.45
- 52 Week High
- OTLK $9.25
- FOXX $12.80
- Technical
- Relative Strength Index (RSI)
- OTLK 46.49
- FOXX N/A
- Support Level
- OTLK $1.65
- FOXX N/A
- Resistance Level
- OTLK $1.97
- FOXX N/A
- Average True Range (ATR)
- OTLK 0.12
- FOXX 0.00
- MACD
- OTLK -0.03
- FOXX 0.00
- Stochastic Oscillator
- OTLK 10.94
- FOXX 0.00
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About FOXX Foxx Development Holdings Inc. Common Stock
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.